Short Interest in RedHill Biopharma Ltd. (NASDAQ:RDHL) Declines By 94.8%

RedHill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large drop in short interest in August. As of August 15th, there was short interest totalling 21,700 shares, a drop of 94.8% from the July 31st total of 417,400 shares. Based on an average trading volume of 304,200 shares, the short-interest ratio is currently 0.1 days. Approximately 1.7% of the company’s stock are short sold.

RedHill Biopharma Stock Down 10.3 %

Shares of RedHill Biopharma stock traded down $0.87 during trading on Tuesday, reaching $7.56. The company’s stock had a trading volume of 113,496 shares, compared to its average volume of 142,924. RedHill Biopharma has a 12-month low of $6.43 and a 12-month high of $82.00. The business has a 50 day moving average price of $220.67 and a 200-day moving average price of $275.16.

Institutional Trading of RedHill Biopharma

An institutional investor recently raised its position in RedHill Biopharma stock. Gagnon Securities LLC lifted its stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) by 32.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the period. Gagnon Securities LLC owned 0.40% of RedHill Biopharma worth $63,000 as of its most recent SEC filing. 7.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on RedHill Biopharma in a research report on Saturday. They set a “hold” rating on the stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.